Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 6Gynecologic 2Gastrointestinal 2Other solid neoplasm 1Head & Neck 1Genitourinary 1CNS 1Breast 1

Conditions

Ovarian Neoplasms 2Fallopian Tube Neoplasms 2

Interventions

Paclitaxel 77pembrolizumab 65Carboplatin 57Bevacizumab 57Specimen Handling 49Magnetic Resonance Spectroscopy 40Cisplatin 35olaparib 31Gemcitabine 27liposomal doxorubicin 25Biopsy 22Taxes 19Cyclophosphamide 18Topotecan 17Nivolumab 17Doxorubicin 16Immunoglobulin G 15niraparib 14Letrozole 14Disulfides 14lenvatinib 13fludarabine 13Surveys and Questionnaires 12Drug Therapy 12Radiotherapy 11Platinum 11atezolizumab 10abemaciclib 10durvalumab 9Fulvestrant 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
berzosertib × Gynecologic × 90 days × Clear all
NCT02595892 2026-04-13

Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
70 enrolled 23 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02627443 2026-04-13

Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
35 enrolled 13 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡